Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.
1620 results about "Blood cell" patented technology
Filter
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A blood cell, also called a hematopoietic cell, hemocyte, or hematocyte, is a cell produced through hematopoiesis and found mainly in the blood. Together, these three kinds of blood cells add up to a total 45% of the blood tissue by volume, with the remaining 55% of the volume composed of plasma, the liquid component of blood.
The invention relates to the technical field of target detection, and discloses a blood cell detection method based on improved YOLOv8. According to the method, a convolutional attention module (CBAM) is introduced, so that the detection performance of the model on a shielded small target is improved; a new loss function S-MPDIOU is set, so that the accuracy and robustness of the loss function are further improved; the multi-scale feature fusion technology is adopted to better capture blood cell information of different sizes, so that the model can more accurately identify small target platelets; the recall rate is improved by improving a non-maximum suppression (NMS) algorithm, and particularly under the condition of dense blood cells or complex forms, the improved NMS algorithm can more effectively solve the overlapping problem and reduce false detection and missing detection. Through testing, the model can accurately identify and position different types of blood cells such as red blood cells, white blood cells and blood platelets in an image, and a new effective method is provided for blood cell detection.
The present application provides a test kit and a POCT blood cell analyzer. The test kit includes a box body, a sealing ring, a microporous sheet, and a back pool body. The box body includes a front pool and a mounting cavity connected to the front pool; the sealing ring is arranged in the mounting cavity and is located on the side of the mounting cavity close to the front pool; the microporous sheet is provided with micropores that allow cells to pass through one by one; the microporous sheet is arranged in the mounting cavity and is located on the side of the sealing ring away from the front pool; the back pool body abuts against the side of the microporous sheet away from the sealing ring, and is used to fix the microporous sheet and the sealing ring on the box body; the back pool body is formed with a drainage cavity, and the front pool and the drainage cavity are connected through micropores. The test kit provided by the present application has a simple structure, is easy to assemble, and is conducive to the processing of the test kit.
The invention provides a blood cell image recognition method based on a multi-scale Vision Transform model, and the method comprises the steps: constructing a multi-scale feature extraction architecture, combining the global modeling capability of a Transform network, carrying out the parallel processing of Patches of different sizes, and fusing the multi-scale information, thereby achieving the recognition of a blood cell image. The cells in the blood smear can be comprehensively perceived from microscopic details to macroscopic contexts, so that not only is the adaptability of the model to cellsize difference and morphological diversity enhanced, but also the recognition stability under the conditions of cell overlapping and dyeing difference in a complex visual field is improved; the accuracy and calculation efficiency of cell classification and counting are effectively improved, and full-process automation from visual field quality evaluation to automatic cell recognition and counting is achieved.
The invention relates to a medical image processing and recognition technology, in particular to a blood cell automatic detection method based on a grading strategy, which comprises the following steps: acquiring a blood cell image set with a label, performing data enhancement on the data set to obtain a first training data set, and selecting a minority class of samples in the first training data set as a second training data set; training a secondary classification network by using the second training data set; constructing an improved YOLOv8 target detection algorithm model, and if the category output by a detection head in the YOLOv8 target detection algorithm model is not a minority category, directly outputting a detection result; and if the category of the single cell image output by the detection head is a minority category, inputting the single cell image into a pre-trained secondary classification network, and obtaining a final category probability by combining the confidence of the secondary classification network with an improved YOLOv8 target detection algorithm model. The method can improve the detection accuracy and the detection rate, and is suitable for the scene of peripheralblood cell detection.
The invention discloses a hematology analyzer and a bubble discharging method. The hematology analyzer comprises a flowing chamber, a pressure source, a first control valve, a second control valve and a third control valve, the flowing chamber comprises a liquid containing cavity, a first liquid inlet, a second liquid inlet and a liquid outlet, the first liquid inlet, the second liquid inlet and the liquid outlet are communicated with the liquid containing cavity, the first control valve is connected with the first liquid inlet through a pipeline, and the second control valve is connected with the liquid outlet through a pipeline. The third control valve is connected with the second liquid inlet through a pipeline, and the pressure source is connected with at least one of the first liquid inlet and the second liquid inlet through a pipeline; when the first liquid exists in the liquid containing cavity, the pressure source is matched with the first control valve, the second control valve and the third control valve to provide positive pressure and negative pressure for the liquid containing cavity, the liquid containing cavity is filled with liquid, second liquid is obtained, and bubbles in the second liquid are smaller than bubbles in the first liquid. Therefore, bubbles of the liquid in the flow chamber can be discharged through a simple structure.
The invention discloses a bone marrowcell classification and identification method based on an SCKannform neural network, and the method comprises the following steps: 1, constructing an SCKannform neural network model which comprises a Kannform encoder, an SCConv encoder, and a global-local attention encoder; 2, establishing and preprocessing a bone marrowblood celldata set, and dividing the data set into a training set and a test set; step 3, using the training set to train the SCKannform neural network model, and adjusting and optimizing the parameters of the SCKannform neural network model in combination with the bone marrowblood cell image characteristics; and step 4, using a test set to test the trained evaluation SCKannformer neural network model, further obtaining a network model, and finally realizing a bone marrow blood cell image classification and identification function. According to the method, the complexity of cell classification in the microscopic image can be effectively handled, and accurate classification of forty types of bone marrow blood cells is realized.
Disclosed are methods, means, and compositions of matter useful for the stimulation of angiogenesis directly by administration of membrane vesicles, such as fibroblast-derived exosomes, and / or through induction of angiogenic cytokines from blood cells contacted with fibroblast-derived exosomes. The invention provides means of treating conditions in which angiogenesis is beneficial through local or systemic administration of exosomes, including those derived from fibroblasts, wherein the fibroblasts are cultured under basal conditions or conditions of hypoxia. In other embodiments exosomes derived from fibroblasts are utilized to augment endogenous regenerative processes, such as hematopoiesis, angiogenesis and neurogenesis, as well as augment regenerative processes stimulated by administration of exogenous therapeutics such as cells, growth factors, or genes.
A blood cell-based therapeutic agent delivery system is disclosed. A blood cell-based therapeutic agent delivery vehicle is useful for delivering a therapeutic agent into a recipient organ cell. The blood cell-based therapeutic agent delivery vehicle is made by a method comprising encapsulating the therapeutic agent into a lipid nanoparticle to produce a therapeutic agent-containing lipid nanoparticle, and transfecting the therapeutic agent- containing lipid nanoparticle into a blood cell by incubating the therapeutic agent-containing lipid nanoparticle with the blood cell to form a transfected blood cell. The administration of the transfected blood cell causes the transfected blood cell to be in close proximity to or direct contact with the recipient organ cell, thereby causing a transfer of the therapeutic agent into the recipient organ cell. A composition for a blood cell-based therapeutic agent delivery vehicle for use in delivering a therapeutic agent into a recipient organ cell is also disclosed.
The invention provides a blood smear device and method for a clinical laboratory. The method comprises the following steps: collecting a staining image of a blood smear; segmenting a gathering region and a sparse region of the blood cells in the blood smear from the dyed image, and determining edge features of each blood cell in the dyed image; performing overlapping analysis on the overlapped blood cells in the aggregation area based on the edge features of the blood cells in the aggregation area to obtain an overlapping influence area of the blood cells in the aggregation area; based on the edge features of the blood cells in the sparse region, reconstructing gaps among the blood cells in the sparse region to obtain a gap reconstruction region of the blood cells in the sparse region; determining the density distribution characteristics of the blood cells in the dyeing image according to the overlapping influence area and the gap reconstruction area; and detecting the uniformity of the blood smear according to the density distribution characteristics. By adopting the scheme of the invention, the blood cell distribution condition can be accurately identified under complex interference factors.
The invention discloses a concentrated platelet product, a production process, a platelet preserving fluid and a storage method, and belongs to the technical field of biology. The production process comprises the following steps: taking fresh anticoagulantwhole blood, shaking and depolymerizing; performing light centrifugation on the fresh anticoagulantwhole blood subjected to shaking depolymerization to obtain upper-layer platelet-rich plasma I and lower-layer blood cells I; performing gradient centrifugation on the lower-layer blood cells I to obtain upper-layer and lower-layer red blood cells II containing an albuginea layer, plasma and a small amount of red blood cells; performing gradient centrifugation on the upper layer to obtain platelet-rich plasma II and lower-layer red blood cells III; combining the platelet-rich plasma I and the platelet-rich plasma II to obtain mixed platelet-rich plasma I; centrifuging the mixed platelet-rich plasma I to obtain upper-layer mixed platelet-rich plasma II and lower-layer red blood cells IV; centrifuging the upper-layer mixed platelet-rich plasma II to obtain upper-layer plasma and lower-layer platelets V; and adding a certain amount of plasma or platelet preserving fluid into the platelet V to obtain the concentrated platelet product.
In some embodiments, a method for classifying elements of a blood sample is provided, the method including: digitally staining an image of the blood sample using a trained machine learning model to generate a digitally stained image; extracting one or more intermediate features generated by the trained machine learning model during the digital staining of the image; providing the one or more extracted intermediate features to a trained multi-class classifier; and employing the trained multi-class classifier to classify at least one element in the blood sample based on the one or more extracted intermediate features. Many other embodiments are also provided.
The invention discloses an MYH9-RD auxiliary screening system and an MYH9-RD auxiliary screening method based on blood cell morphology. Comprising an image acquisition module, an image detection module and an image analysis module, wherein the image acquisition module is responsible for acquiring a Wright stained peripheral blood image of a case to be screened; the image detection module is responsible for acquiring an independent image of each blood cell; the image analysis module is responsible for acquiring blood cell category information, leukocyte form information and platelet size information; the counting and processing module is responsible for generating an analysis result of a case to be screened; the related disease judgment module is responsible for generating an MYH9-RD screening result; and the result output module is responsible for outputting the screening result. According to the method, the morphology of the special cells of the peripheral blood is accurately identified and the number of the cells is accurately calculated through an artificial intelligencealgorithm, so that the defects of incomplete visual capture and easy fatigue of human beings are overcome, misdiagnosis and missed diagnosis caused by personal errors or subjective differences are reduced, accurate identification of the cell morphology is realized, and the working efficiency is greatly improved; and early, rapid and efficient screening of the MYH9-RD is facilitated.
A blood cell analyzer (100) and a blood cellanalysis method (300). The blood cellanalysis method (300) comprises: sucking a blood sample to be tested; preparing a first determination sample and obtaining first optical information; preparing a second determination sample and obtaining second optical information; generating a first leukocyte classification scatter diagram and a second leukocyte classification scatter diagram; determining a first counting result of neutrophils of the to-be-detected blood sample based on the first leukocyte classification scatter diagram and the second leukocyte classification scatter diagram; determining an actual distribution area of neutrophils from the first leukocyte classification scatter diagram; based on a reference distribution region of neutrophils of a reference leukocyte classification scatter diagram of the normal blood sample, determining a leaf-division nucleophore distribution region from the actual distribution region; determining a second counting result of the cells falling into the leaf-separating nucleogranulocyte distribution area; and based on the first counting result and the second counting result, determining a counting result of the rod-shaped nuclear granulocytes in the to-be-detected blood sample.
The invention discloses a blood cell analyzer and a blood cellanalysis method, and the blood cell analyzer obtains a reticulocyte detection result according to projection data of erythrocyte particles in the extension direction of reticulocyte particles. The overlapping number of reticulocytes and other erythrocyte particles is small, so that the accuracy of a detection result can be effectively improved; the hematology analyzer can automatically adjust the projection direction according to the distribution data of the red blood cell particles, so that the hematology analyzer can be suitable for detection of blood cells in different forms, and the compatibility of the hematology analyzer in multi-species detection is improved.
The present disclosure describes gene editing systems and therapeutics for use in treating VEXAS syndrome. In particular, the disclosure describes lipid nanoparticles that enhance the targeted delivery of gene editing systems and therapeutics to blood cellprogenitor cells, enabling treatment of VEXAS syndrome, in vivo or ex vivo.
The invention discloses an anti-lipopolysaccharide factor rALF-like protein and application thereof, and belongs to the technical field of molecular biology. The anti-lipopolysaccharide factor rALF-like protein provided by the invention belongs to secretory protein, the rALF-like protein can be competitively combined with an LPS structural domain of bacteria to achieve the purpose of inhibiting inflammation, and the expression of the coding gene Pv-ALF-like gene in blood cells, hepatopancreas, gill and intestinal tissues is remarkably up-regulated, so that the anti-lipopolysaccharide factor rALF-like protein can be used for inhibiting inflammation. The rALF-like protein disclosed by the invention has antibacterial and antiviral effects, lays a foundation for developing antibacterial and antiviral drugs and functional feed additives, and plays an important role in improving the resistance link of prawns.
The invention relates to the field of plasma separation and detection, in particular to a composition for separating plasma and a using method thereof. The composition comprises: a phase change component, which is selected from n-alkanes, which are selected from at least one of n-tetradecane, n-pentadecane, n-hexadecane, n-heptadecane, n-octadecane, n-nonadecane, n-eicosane, n-heneicosane or n-docosane; a liquid phase carrier component, wherein the liquid phase carrier component is selected from silicone oil; the structural framework and rheology regulation and control component comprises fumed silica, and the structural framework and rheology regulation and control component comprises fumed silica; the dispersion and stabilization auxiliary agent component is selected from at least one of TiO2 and BaSO4, the density adjusting filler component is selected from at least one of TiO2 and BaSO4, and the dispersion and stabilization auxiliary agent component comprises a silanecoupling agent. According to the device, plasma and blood cells can be reliably, rapidly and effectively separated only through one-time low-temperature centrifugation, and remixing caused by transportation jolting can be avoided.
The invention provides a blood cell migration capability detection method and system, and belongs to the technical field of data processing. The method comprises the following steps: collecting corresponding experimental information of blood cells in a cellscratch test, wherein the experimental information comprises an initial image and correlation time corresponding to the initial image; obtaining a first subimage and a second subimage from the initial image, and calculating the similarity between the first subimage and the second subimage; screening the initial image according to the similarity degree to obtain a target image; performing edge identification on the target image to obtain target edge information, and performing curve fitting on the target edge information to obtain a target curve corresponding to the target image; target time corresponding to the target image is obtained from the correlation time, and a target detection result corresponding to the blood cells is determined according to the target time and the target curve. The problem that in the prior art, edge points of irregular areas cannot be accurately obtained, and therefore accurate evaluation of the blood cell migration capacity is affected is solved.
The current application reveals a method, apparatus, device, and storage medium for detecting micro residual lesions, falling within the domain of medical detection technology. This method is based on differentiated deep whole-exome / targeted drug sequencing and tissue-blood cell-plasma co-capture technology, and 100,000× ultra-high depth personalized / high evidence hotspot combination panel sequencing to evaluate tiny residual lesions and tumor evolution / second primary in plasma samples. It resolves the challenges of existing techniques, such as elevated tissue detection thresholds, restricted tracking locations, inadequate detection sensitivity and precision, or elevated costs when ctDNA concentrations in the bloodstream are minimal. Furthermore, it surmounts the challenge of simultaneously achieving personalized tracking detection and monitoring tumor evolution or second / primary detection. It markedly boosts the precision of forecasting the likelihood of recurrence following patient therapy within a restricted budget.
The utility model discloses a portable peripheralblood cell counter which comprises a glass slide and a cover glass, and the cover glass is positioned at the upper end of the glass slide; the carrying and placing frame is arranged at the lower end of the glass slide, a rectangular placing open groove is formed in the upper end face of the carrying and placing frame, L-shaped positioning pieces are fixed to the four corners of the upper end of the rectangular placing open groove in the carrying and placing frame, and the glass slide is located in the rectangular placing open groove and clamped among the four L-shaped positioning pieces; the semicircular through groove is formed in the middle of the front end face and the rear end face of the carrying and placing frame, and the semicircular through groove vertically penetrates through the carrying and placing frame. According to the blood cell counter, external protection of glass slides and cover glass is achieved, the effect that each group of cover glass and glass slides are separated is achieved, and therefore the problems that a main body of an existing blood cell counter used for counting is made of glass slides and cover glass, the glass slides and the cover glass are prone to colliding with each other during placement, damage can occur, and peripheral blood cell counting is affected are effectively solved.